Dersimelagon (MT-7117)
Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
Phase 3Active
Key Facts
Indication
Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
Phase
Phase 3
Status
Active
Company
About Tanabe Pharma America
Tanabe Pharma America is a U.S.-based pharmaceutical company established in 2017 as the American arm of the long-standing Japanese firm Tanabe Pharma Corporation. The company is in the commercial and late-stage clinical development stage, with a marketed product for ALS (RADICAVA/edaravone, recently transferred) and a late-phase pipeline asset, dersimelagon, for rare photodermatoses. TPA's strategy centers on advancing small molecule therapies for severe neurological and rare diseases, building on its parent company's extensive R&D heritage. It operates as a private, revenue-generating entity, though specific financials are not disclosed.
View full company profileTherapeutic Areas
Other Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) Drugs
| Drug | Company | Phase |
|---|---|---|
| MT-7117 | Mitsubishi Tanabe Pharma | Phase 3 |